2024-05-27 07:02:07 ET
Summary
- Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss.
- The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune.
- Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy.
Altimmune Inc. ( ALT ) is completing a Phase 2 clinical trial of pemvidutide , an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear to be very encouraging in terms of current and future growth, so much so that my hypothetical projection of the share price projects it well above $100 in 2030. To proceed on its path, however, Altimmune needs to find an important partnership that allows it to compete on par with the more renowned Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) as well as other players. The potential of the drug, in my opinion, is very important, given the clinical results and market potential, and the chances of success should have a favorable wind. My rate is Buy.
Business Overview
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on one core product called Pemvidutide, designed and developed for the treatment of obesity and liver disease....
Read the full article on Seeking Alpha
For further details see:
Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns